Aurora Cannabis (TSE:ACB) Sets New 1-Year Low – Time to Sell?

Aurora Cannabis Inc. (TSE:ACB)’s stock price reached a new 52-week low during trading on Monday . The stock traded as low as C$4.33 and last traded at C$4.35, with a volume of 164190 shares traded. The stock had previously closed at C$4.47.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Canaccord Genuity Group set a C$10.00 price target on shares of Aurora Cannabis and gave the company a “buy” rating in a research report on Tuesday, January 27th. ATB Cormark Capital Markets lowered their price objective on shares of Aurora Cannabis from C$9.00 to C$8.50 and set an “outperform” rating for the company in a report on Thursday, December 11th. Two research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of C$9.25.

Aurora Cannabis Stock Performance

The company has a market capitalization of C$245.55 million, a PE ratio of -2.89 and a beta of 0.26. The company has a 50 day moving average of C$5.07 and a two-hundred day moving average of C$6.15. The company has a debt-to-equity ratio of 25.02, a current ratio of 3.06 and a quick ratio of 2.48.

Aurora Cannabis (TSE:ACB) last posted its quarterly earnings data on Wednesday, February 4th. The company reported C$0.03 earnings per share (EPS) for the quarter. Aurora Cannabis had a negative return on equity of 1.15% and a negative net margin of 1.69%.The business had revenue of C$94.19 million during the quarter. As a group, equities research analysts predict that Aurora Cannabis Inc. will post -0.22 earnings per share for the current year.

About Aurora Cannabis

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.